Report · S7680
FDA contract listing — selected Stanford award 75F40120C00176
An FDA contract listing names Stanford University for 75F40120C00176, independently of the MaxFuse acknowledgement. The requirement concerns coronavirus research. Its wording differs from a later FDA presentation using the same identifier; the amendment or naming history remains unresolved. This supports a public institutional funding link, without establishing Nolan as the named principal investigator or a classified programme.
Read the document at fda.govWhat we checked
Root received/hash-verified original 5-leaf FDA PDF and read native extracted leaves 1. One selected native layout actually viewed; full document graphics/layouts and executed agreements/modifications remain unreviewed. Stanford financial columns verified on first leaf; other four leaves unreviewed.
Partial root native PDF text and selected layout review
How we check sources
Not checked yet
- Full parent native layouts/graphics and complete illustrated document remain unreviewed; one selected layout viewed.
- Original executed contracts, modifications, task statements and current obligations/payment history not reviewed.
- Institution/project support is not a named Nolan principal-investigator finding, personal payment or classified UAP approach.
- Same contract has differing award-table and later presentation descriptions; original amendment/naming history remains unknown.
- Published and file metadata dates remain distinct. No operational study/protocol, patient records or claimed personal briefing reviewed.
Cite this record
U.S. Food and Drug Administration. FDA contract listing — selected Stanford award 75F40120C00176. BioParity S7680. https://bioparity.io/sources/S7680Record data (JSON)